Paratek Pharmaceuticals, Inc. PRTKannounced that the FDA has accepted two new drug applications (NDAs), seeking approval of its antibiotic candidate, omadacycline. The NDAs were granted priority review, thus speeding up the review process. A decision is expected in October 2018.
Paratek's (PRTK) NDAs for Omadacycline Get Priority Review
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться